✦ LIBER ✦

Multiple myeloma vaccine exhibits potent antitumour activity in murine models

Book ID: 120865632
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2001
Weight: 133 KB
Volume: &NA;
Category: Article
ISSN: 1173-8324
DOI: 10.2165/00128413-200113130-00020

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The potent bisphosphonate ibandronate do

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma

✍ Claire M. Shipman; Karin Vanderkerken; Michael J. Rogers; Jennifer M. Lippitt; K 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB

The polo-like kinase inhibitor BI 2536 e

The polo-like kinase inhibitor BI 2536 exhibits potent activity against malignant plasma cells and represents a novel therapy in multiple myeloma

✍ Helen J. Stewart; Lyudmila Kishikova; Fiona L. Powell; Sally P. Wheatley; Timoth 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 997 KB

AR36A36.11.1, a monoclonal antibody targ

AR36A36.11.1, a monoclonal antibody targeting CD59, enhances complement activity and exhibits potent in vivo efficacy in multiple human cancer models

✍ Baldwin C. Mak; Fortunata McConkey; Ningping Feng; Kevin O’Reilly; Daniel Rubins 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 69 KB

A small molecule, LLL12 inhibits constit

A small molecule, LLL12 inhibits constitutive STAT3 and IL-6-induced STAT3 signaling and exhibits potent growth suppressive activity in human multiple myeloma cells

✍ Li Lin; Don M. Benson Jr.; Stephanie DeAngelis; Courtney E. Bakan; Pui-Kai Li; C 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 French ⚖ 891 KB

## Abstract We characterized the effects of a newly developed signal transducers and activators of transcription 3 (STAT3) inhibitor, LLL12 in multiple myeloma (MM) cells. LLL12 specifically inhibited STAT3 phosphorylation, nuclear localization, DNA binding activity, down‐regulated STAT3 downstream

JS-K has potent anti-angiogenic activity

JS-K has potent anti-angiogenic activity in vitro and inhibits tumour angiogenesis in a multiple myeloma model in vivo

✍ Tanyel Kiziltepe; Kenneth C. Anderson; Jeffery L. Kutok; Lee Jia; Kenneth M. Bou 📂 Article 📅 2010 🏛 Pharmaceutical Press 🌐 English ⚖ 489 KB

447 POSTER ARRY-520, a KSP inhibitor wit

447 POSTER ARRY-520, a KSP inhibitor with potent in vitro and in vivo efficacy and pharmacodynamic activity in models of multiple myeloma

✍ R. Woessner; B. Tunquist; E. Chlipala; M. Humphries; D. Trawick; A. Cox; P. Lee; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 81 KB